Primary prostatic adenocarcinoma (pPC) undergoes genomic evolution secondary to therapy-related selection pressures as it transitions to metastatic noncastrate (mNC-PC) and castrate resistant (mCR-PC) disease. Next generation sequencing results were evaluated for pPC (n = 97), locally advanced disease (involving urinary bladder/rectum, n = 12), mNC-PC (n = 21), and mCR-PC (n = 54). We identified enrichment of TP53 alterations in high-grade pPC, TP53/RB1 alterations in HGNE disease, and AR alterations in metastatic and castrate resistant disease. Actionable alterations (MSI-H phenotype and HRR genes) were identified in approximately a fifth of all cases. These results help elucidate the landscape of genomic alterations across the clinical spectrum of prostate cancer.
Prostate cancer and prostatic diseases. 2024 Feb 27 [Epub ahead of print]
Surendra Dasari, Michael R McCarthy, Antonina A Wojcik, Beth A Pitel, Arpan Samaddar, Burak Tekin, Rumeal D Whaley, Aditya Raghunathan, Loren Herrera Hernandez, Rafael E Jimenez, Brad J Stish, R Houston Thompson, Bradley C Leibovich, Stephen A Boorjian, R Jeffrey Karnes, Daniel S Childs, J Fernando Quevedo, Eugene D Kwon, Lance C Pagliaro, Brian A Costello, Kevin C Halling, John C Cheville, Benjamin R Kipp, Sounak Gupta
Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA., Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA., Department of Urology, Mayo Clinic, Rochester, MN, USA., Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA., Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. .